Geode Capital Management
ASBP

Geode Capital Management’s Aspire Biopharma ASBP Stock Holding History

Geode Capital Management’s Portfolio ASBP Stock Details ASBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$44.7K Buy
1,446
+1,240
+602% +$66K ﹤0.01% 4342
2025
Q4 		$32.7K Sell
206
-2
-1% -$500 ﹤0.01% 4313
2025
Q3 		$51.5K Buy
+208
New +$104K ﹤0.01% 4288

Other funds holding ASBP

UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CA
Crewe Advisors Salt Lake City, Utah $1.17B AUM 29.21% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
CA
Crossingbridge Advisors Pleasantville, New York $553M AUM 1.29% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
VWM
Valley Wealth Managers Paramus, New Jersey $1.55B AUM 28.47% 1-Year Est. Return

Geode Capital Management's ASBP Position: Q1 2026 in Review

Geode Capital Management increased its Aspire Biopharma (ASBP) stake by 602% in Q1 2026, buying an estimated $66K and bringing the position to 1,446 shares worth $44.7K. The position accounts for ﹤0.01% of the portfolio, ranked #4342.

Geode Capital Management first reported a position in ASBP in Q3 2025 and has held it in 3 quarters since. The position peaked at $51.5K in Q3 2025. 12 funds tracked by Wall St. Rank hold ASBP as of Q1 2026.

  • Geode Capital Management held 1,446 shares of Aspire Biopharma worth $44.7K as of Q1 2026.
  • Geode Capital Management bought 1,240 Aspire Biopharma shares in Q1 2026, an estimated $66K.
  • Aspire Biopharma made up ﹤0.01% of Geode Capital Management's portfolio in Q1 2026, its #4342 holding.
  • Geode Capital Management first reported a position in Aspire Biopharma in Q3 2025 and has held it in 3 quarters since.
  • Geode Capital Management's Aspire Biopharma position peaked at $51.5K in Q3 2025.
  • 12 funds tracked by Wall St. Rank held Aspire Biopharma as of Q1 2026.

Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.